TY - JOUR
T1 - Dosing of insulin glargine in the treatment of type 2 diabetes
AU - Barnett, Anthony
PY - 2007/6/1
Y1 - 2007/6/1
N2 - BACKGROUND: Type 2 diabetes is a progressive disease characterized by insulin resistance and declining beta-cell function, often leading to a requirement for insulin therapy to maintain good glycemic control and prevent diabetes-associated complications. Adequate insulin dosing is crucial to the achievement of good glycemic control with minimal hypoglycemia, and dose titration immediately following insulin initiation is needed to ensure its success. Insulin may be initiated as an add-on therapy to oral treatment using a single evening basal insulin dose and titrating according to fasting blood glucose (FBG) levels (with an ideal target of or=5.6-or=6.7-or=7.8-or=10 mmol/L [>or=100-or=120-or=140-or=180 mg/dL], respectively, in the absence of plasma glucose
AB - BACKGROUND: Type 2 diabetes is a progressive disease characterized by insulin resistance and declining beta-cell function, often leading to a requirement for insulin therapy to maintain good glycemic control and prevent diabetes-associated complications. Adequate insulin dosing is crucial to the achievement of good glycemic control with minimal hypoglycemia, and dose titration immediately following insulin initiation is needed to ensure its success. Insulin may be initiated as an add-on therapy to oral treatment using a single evening basal insulin dose and titrating according to fasting blood glucose (FBG) levels (with an ideal target of or=5.6-or=6.7-or=7.8-or=10 mmol/L [>or=100-or=120-or=140-or=180 mg/dL], respectively, in the absence of plasma glucose
UR - https://www.scopus.com/pages/publications/34547601276
U2 - 10.1016/j.clinthera.2007.06.018
DO - 10.1016/j.clinthera.2007.06.018
M3 - Review article
C2 - 17692716
VL - 29
SP - 987
EP - 999
JO - Clinical Therapeutics
JF - Clinical Therapeutics
IS - 6
ER -
